Somerville Kurt F Has $651,000 Holdings in Thermo Fisher Scientific Inc. $TMO

Somerville Kurt F grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,605 shares of the medical research company’s stock after buying an additional 25 shares during the period. Somerville Kurt F’s holdings in Thermo Fisher Scientific were worth $651,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. REAP Financial Group LLC increased its stake in Thermo Fisher Scientific by 131.1% in the second quarter. REAP Financial Group LLC now owns 104 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 59 shares in the last quarter. Sax Wealth Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 152.6% in the 2nd quarter. Sax Wealth Advisors LLC now owns 1,579 shares of the medical research company’s stock valued at $640,000 after buying an additional 954 shares during the period. WestEnd Advisors LLC increased its position in shares of Thermo Fisher Scientific by 28.5% in the 2nd quarter. WestEnd Advisors LLC now owns 85,492 shares of the medical research company’s stock valued at $34,665,000 after buying an additional 18,950 shares in the last quarter. BankPlus Trust Department lifted its holdings in Thermo Fisher Scientific by 4.6% during the second quarter. BankPlus Trust Department now owns 2,752 shares of the medical research company’s stock worth $1,116,000 after acquiring an additional 121 shares in the last quarter. Finally, Shell Asset Management Co. grew its stake in Thermo Fisher Scientific by 6.6% in the second quarter. Shell Asset Management Co. now owns 22,472 shares of the medical research company’s stock valued at $9,111,000 after acquiring an additional 1,390 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TMO. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. HSBC restated a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $591.16.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $539.54 on Wednesday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The firm has a fifty day simple moving average of $484.90 and a 200 day simple moving average of $447.60. The stock has a market capitalization of $203.73 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.